Sanofi Withdrawing NDA for Lixisenatide

Sanofi Withdrawing NDA for Lixisenatide 

Sanofi announced they are withdrawing their New Drug Application (NDA) for their once-daily GLP-1 lixisenatide from the FDA. The combination of lixisenatide and Lantus® (basal insulin), the investigational LixiLan fixed-ratio product, remains on schedule to enter into phase 3 in the first half of 2014.